{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:42:02Z","timestamp":1771004522718,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,9,27]],"date-time":"2007-09-27T00:00:00Z","timestamp":1190851200000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:p><jats:bold><jats:sc>Abstract<\/jats:sc>:\u2002<\/jats:bold>  <jats:bold>Behcet's disease (BD) is a chronic, relapsing, multisystem disease. In some patients, ocular involvement can lead to severe vision impairment despite immunosuppressive therapy. Since high levels of circulating TNF\u2010\u03b1 have been found both in peripheral blood and aqueous humor of patients with active BD, we evaluated the efficacy of anti\u2010TNF\u2010\u03b1 therapy in seven patients with severe ocular involvement resistant to previous treatment. Seven patients with sight\u2010threatening relapsing uveitis refractory to immunosuppressive regimens received intravenously infliximab, at a dose of 3\u20135 mg\/kg, on week 0\u20132\u20134 and then every 6\u20138 weeks, in combination with low\u2010dose prednisone and methotrexate or azathioprine. Efficacy was assessed in terms of number and severity of relapses of posterior uveitis, visual acuity, and reduction of corticosteroids and immunosuppressive drugs. After a mean follow\u2010up period of 23 months, the total number of relapses dropped to 6, compared to the 21 observed in an equivalent period of time before treatment. The visual acuity improved in 4 eyes, while it remained stable in 9. Therapy with infliximab considerably reduced the required daily dose of both corticosteroids and immunosuppressive drugs. In our experience infliximab proved to be safe and effective in controlling both the number and intensity of cases of posterior uveitis and the extraocular manifestations of BD. It also allowed a reduction of corticosteroids and immunosuppressive drugs required to control the disease. However, ocular and systemic manifestations tended to recur after drug withdrawal or when the interval between infliximab courses was longer than 8 weeks. Moreover, infliximab administration is costly and requires hospital admission.<\/jats:bold> <\/jats:p>","DOI":"10.1196\/annals.1423.050","type":"journal-article","created":{"date-parts":[[2007,10,2]],"date-time":"2007-10-02T20:20:20Z","timestamp":1191356420000},"page":"474-484","source":"Crossref","is-referenced-by-count":45,"title":["Anti\u2010TNF\u2010\u03b1 Therapy in Seven Patients with Beh\u00e7et's Uveitis"],"prefix":"10.1111","volume":"1110","author":[{"given":"S.","family":"TOGNON","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"GRAZIANI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"MARCOLONGO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,9,27]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2005.04.009"},{"key":"e_1_2_5_3_2","first-page":"20","article-title":"Pathogenesis and therapy of Beh\u00e7et's disease","volume":"12","author":"Emmi L.","year":"1997","journal-title":"Ann. Ital. Med."},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.11.996"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2003.10.009"},{"issue":"42","key":"e_1_2_5_6_2","first-page":"S13\/B4","article-title":"Evaluation of the International Criteria for Beh\u00e7et's Disease (ICBD)","volume":"24","author":"Report of the International Team for the Revision of the International Criteria for Beh\u00e7et's Disease (ITR\u2010ICBD)","year":"2006","journal-title":"[abstract]. Clin. Exp. Rheumatol."},{"issue":"42","key":"e_1_2_5_7_2","first-page":"S14\/B10","article-title":"Revision of the International Criteria for Beh\u00e7et's Disease","volume":"24","author":"ITR\u2010ICBD","year":"2006","journal-title":"[abstract]. Clin. Exp. Rheumatol."},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.03.022"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2003.07.018"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2006.06.002"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21231"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-5-200403020-00025"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2003.037192"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(03)00406-8"},{"key":"e_1_2_5_15_2","first-page":"1362","article-title":"Efficacy, safety and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et's disease with refractory uveoretinitis","volume":"31","author":"Ohno S.","year":"2004","journal-title":"J. Rheumatol."},{"issue":"4","key":"e_1_2_5_16_2","first-page":"s14","article-title":"Infliximab in refractory uveitis due to Beh\u00e7et's disease","volume":"22","author":"Wechsler B.","year":"2004","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_2_5_17_2","first-page":"1621\/292","article-title":"Efficacy and safety of treatment with infliximab in refractory posterior uveitis\/five years follow\u2010up","volume":"54","author":"Lopez\u2010Gonzalez R.","year":"2006","journal-title":"[abstract]. Arthrits Rheum."},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0755-4982(05)84079-5"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-006-9006-9"},{"issue":"42","key":"e_1_2_5_20_2","first-page":"S25\/D4","article-title":"Long term follow\u2010up of infliximab in refractory panuveitis due to Beh\u00e7et's disease","volume":"24","author":"Wechsler B.","year":"2006","journal-title":"[abstract]. Clin. Exp. Rheumatol."},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.123.7.903"},{"issue":"42","key":"e_1_2_5_22_2","first-page":"S29\/E15","article-title":"Infliximab for severe uveitis: forty\u2010six weeks efficacy and safety results from the Remicade European Study for Chronic Uveitis (RESCUE) [abstract]","volume":"24","author":"Bodaghi B.","year":"2006","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0225"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273940600659393"},{"issue":"42","key":"e_1_2_5_25_2","first-page":"S35\/H4","article-title":"Adalimumab: a new modality for sight\u2010threatening uveitis in Beh\u00e7et's disease","volume":"24","author":"Van Laar J.A.M.","year":"2006","journal-title":"[abstract]. Clin. Exp. Rheumatol."},{"issue":"42","key":"e_1_2_5_26_2","first-page":"S36\/H11","article-title":"Adalimumab in Beh\u00e7et's disease: case report [abstract]","volume":"24","author":"Vinagre F.","year":"2006","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.10.1213-b"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.04.038"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct055183"},{"issue":"7442","key":"e_1_2_5_30_2","article-title":"Really expert patients can \u201cempower\u201d doctors","volume":"328","author":"Marcolongo R.","year":"2004","journal-title":"BMJ.com."}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1196%2Fannals.1423.050","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1196\/annals.1423.050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T08:55:34Z","timestamp":1695632134000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1196\/annals.1423.050"}},"subtitle":["Advantages and Controversial Aspects"],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1196\/annals.1423.050"],"URL":"https:\/\/doi.org\/10.1196\/annals.1423.050","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}